Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock

Raju, Bharath; McCullough, Peter A.

doi:10.1002/ejhf.1623

Cited by 2 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, animal studies have shown that cDPP3 significantly affects cardiac contractility with a negative inotropic effect. 123 In particular, high cDPP3 values have been found in severely ill patients with CS. In the OptimaCC study, cDPP3 values were higher in refractory CS than non-refractory CS at inclusion (p = 0.014), at 24 h (p < 0.001) and up to 48 h (p = 0.027).…”

Section: Procizumabmentioning

confidence: 99%

“…Recently, it has been discovered that it is implicated in pathophysiologic processes such as inflammation, BP regulation, and pain modulation. In addition, animal studies have shown that cDPP3 significantly affects cardiac contractility with a negative inotropic effect 123 . In particular, high cDPP3 values have been found in severely ill patients with CS.…”

Section: Other Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors

Riccardi,

Pagnesi,

Chioncel

et al. 2024

European J of Heart Fail

View full text Add to dashboard Cite

Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi‐organ failure and death depending on its severity. Inadequate cardiac contractility or cardiac power secondary to acute myocardial infarction remains the most frequent cause of cardiogenic shock, although its contribution has declined over the past two decades, compared with other causes. Despite some advances in cardiogenic shock management, this clinical syndrome is still burdened by an extremely high mortality. Its management is based on immediate stabilization of haemodynamic parameters so that further treatment, including mechanical circulatory support and transfer to specialized tertiary care centres, can be accomplished. With these aims, medical therapy, consisting mainly of inotropic drugs and vasopressors, still has a major role. The purpose of this article is to review current evidence on the use of these medications in patients with cardiogenic shock and discuss specific clinical settings with indications to their use.

show abstract

Section: Procizumabmentioning

confidence: 99%

Section: Other Agentsmentioning

confidence: 99%

Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors

Riccardi,

Pagnesi,

Chioncel

et al. 2024

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…Well-established humoral markers of adverse outcome in CS include increased transaminase and creatinine levels [30], reflecting hepatic and renal hypoperfusion, and raised plasmatic arterial lactate which is considered an early marker of mitochondrial dysfunction and cellular impairment [31][32][33]. Another known marker is acidosis, which could lead to negative effects on myocardial contractility and impair the response to some vasopressors [34].…”

Section: Biochemical Markersmentioning

confidence: 99%

“…Other markers are currently under investigation, such as fibroblast growth factor-23 (FGF-23), high-sensitive C-reactive protein, angiopoietin-2 and soluble tumor necrosis factor receptor-1 (sTNFR1) [48,49]. Moreover, the Optima CC trial has recently highlighted the role of circulating plasma dipeptidyl dipeptidase 3 [50], as it might predict either refractory CS and 90-day mortality [30,50], even though these results come from a limited study population. Recent research is focusing on the role of micro-RNAs, due to accumulating evidence of their complex involvement in pathophysiological changes in heart disease [51], especially in advance heart failure, even though their prognosticator role in CS is still not completely clear.…”

Section: Biochemical Markersmentioning

confidence: 99%

Risk stratification in cardiogenic shock: a focus on the available evidence

et al. 2021

View full text Add to dashboard Cite

Cardiogenic shock is a clinical syndrome which is defined as the presence of primary cardiac disorder that results in hypotension together with signs of organ hypoperfusion in the state of normovolaemia or hypervolaemia. It represents a complex life-threatening condition, characterized by a high mortality rate, that requires urgent diagnostic assessment as well as treatment; therefore, it is of paramount important to advocate for a thorough risk stratification. In fact, the early identification of patients that could benefit the most from more aggressive and invasive approaches could facilitate a more efficient resource allocation. This review attempts to critically analyse the current evidence on prognosis in cardiogenic shock, focusing in particular on clinical, laboratoristic and echocardiographic prognostic parameters. Furthermore, it focuses also on the available prognostic scores, highlighting the strengths and the possible pitfalls. Finally, it provides insights into future direction that could be followed in order to ameliorate risk stratification in this delicate subset of patients.

show abstract

Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock

Cited by 2 publications

References 13 publications

Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors

Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors

Risk stratification in cardiogenic shock: a focus on the available evidence

Contact Info

Product

Resources

About